Combination Oral Chelation in Adult Patients With Transfusion-dependent Thalassemia and High Iron Burden

被引：9
|
作者：
Hammond, John [1 ]
Thompson, Alexis A. [4 ,5 ]
Fogel, Mark A. [2 ]
Hammond, Katherine [4 ]
Kokroko, Jolene [1 ]
Kwiatkowski, Janet L. [1 ,3 ]
机构：
[1] Childrens Hosp Philadelphia, Div Hematol, 3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA
[2] Childrens Hosp Philadelphia, Div Cardiol, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA
[4] Ann & Robert H Lurie Childrens Hosp Chicago, Div Hematol Oncol, Chicago, IL 60611 USA
[5] Northwestern Univ, Dept Pediat, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2019年 / 41卷 / 01期
关键词：
thalassemia; iron overload; deferasirox; deferiprone; MYOCARDIAL IRON; DEFERIPRONE THERAPY; DEFERASIROX; SAFETY; DEFEROXAMINE; TRIAL; RISK;
D O I：
10.1097/MPH.0000000000001269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
An open-label, pilot study was conducted to evaluate deferasirox/deferiprone combination chelation therapy in adult patients with transfusion-dependent thalassemia and severe iron overload. Enrollment proved difficult. Nine patients (median age, 27.4 y; ferritin, 4965 ng/mL; liver iron concentration, 28.5 mg/g dry weight; cardiac T2*, 13.3 ms) received treatment. Two were withdrawn for treatment-related adverse effects. Arthralgia (4 patients) and gastrointestinal symptoms (5 patients) were common; no episodes of neutropenia/agranulocytosis occurred. Adherence difficulties were common. Of 6 patients with 12 to 18 months follow-up, 3 showed improvement in cardiac T2* and 2 in liver iron. Combination oral chelation may be effective but adverse effects and adherence challenges may limit efficacy.
引用
收藏
页码：E47 / E50
页数：4
相关论文
共 50 条
  • [11] Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives
    Bayanzay, Karim
    Alzoebie, Lama
    JOURNAL OF BLOOD MEDICINE, 2016, 7 : 159 - 169
  • [12] Beyond blood transfusions: exploring iron chelation therapies in transfusion-dependent beta-thalassemia
    Talha, Muhammad
    Ali, Mohammad Haris
    Hurjkaliani, Sonia
    Rahmat, Zainab Syyeda
    Sadia, Haleema
    Al Hasibuzzaman, Md.
    Uzair, Ahsan Ul Qayyum
    ANNALS OF MEDICINE AND SURGERY, 2025, 87 (01): : 13 - 17
  • [13] Heterogeneity of myocardial iron distribution in response to chelation therapy in patients with transfusion-dependent anemias
    Hanneman, Kate
    Raju, Vikram M.
    Moshonov, Hadas
    Ward, Richard
    Wintersperger, Bernd J.
    Crean, Andrew M.
    Ross, Heather
    Nguyen, Elsie T.
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2013, 29 (07): : 1517 - 1526
  • [14] Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions
    Saliba, Antoine N.
    Harb, Afif R.
    Taher, Ali T.
    JOURNAL OF BLOOD MEDICINE, 2015, 6 : 197 - 209
  • [15] Progression of liver fibrosis can be controlled by adequate chelation in transfusion-dependent thalassemia (TDT)
    Maira, D.
    Cassinerio, E.
    Marcon, A.
    Mancarella, M.
    Fraquelli, M.
    Pedrotti, P.
    Cappellini, M. D.
    ANNALS OF HEMATOLOGY, 2017, 96 (11) : 1931 - 1936
  • [16] Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Michael D. Diamantidis
    Nikolaos Neokleous
    Aleka Agapidou
    Evaggelia Vetsiou
    Achilles Manafas
    Paraskevi Fotiou
    Efthymia Vlachaki
    International Journal of Hematology, 2016, 103 : 537 - 544
  • [17] Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?
    Diamantidis, Michael D.
    Neokleous, Nikolaos
    Agapidou, Aleka
    Vetsiou, Evaggelia
    Manafas, Achilles
    Fotiou, Paraskevi
    Vlachaki, Efthymia
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (05) : 537 - 544
  • [18] Subcutaneous iron chelation therapy, oral iron chelation therapy, or both in patients with thalassemia?
    Babrs, Gihan M.
    Abd El-Hakeem, Mohammed A.
    EGYPTIAN JOURNAL OF HAEMATOLOGY, 2013, 38 (02): : 51 - 55
  • [19] Australian guidelines for the assessment of iron overload and iron chelation in transfusion-dependent thalassaemia major, sickle cell disease and other congenital anaemias
    Ho, P. J.
    Tay, L.
    Lindeman, R.
    Catley, L.
    Bowden, D. K.
    INTERNAL MEDICINE JOURNAL, 2011, 41 (07) : 516 - 524
  • [20] Iron-chelation therapy with oral chelators in patients with thalassemia major
    Uygun, Vedat
    Kurtoglu, Erdal
    HEMATOLOGY, 2013, 18 (01) : 50 - 55
12345